In partnership with the University of Minnesota College of Pharmacy, ASHP is pleased to have launched the inaugural cohort of the Pharmacogenomics (PGx) AcceleratorTM.
Three institutions, including Texas A&M Irma Lerma Rangel School of Pharmacy, Froedtert Health, and Wentworth-Douglass Hospital, have joined the first cohort as part of their commitment to advancing patient care through pharmacogenomics.
The PGx Accelerator aims to improve the health of millions across the U.S. by personalizing medication therapies based on an individual’s pharmacogenomic profile. The program supports clinicians in implementing and growing pharmacogenomic services at their institutions and offers a wide range of learning experiences, including webinars and events with subject matter experts, access to multiple resources and activity streams, and individualized support from an implementation coach.
The cohort’s success relies on the evidence-based implementation science methodology and the all-teach-all-learn approach, along with dedicated coaches and field experts assigned to each institution as the program works to:
- Catalyze pharmacy leadership in pharmacogenomics service development.
- Accelerate the design and implementation of comprehensive pharmacogenomics services that demonstrate value to stakeholders (patients, health-system leaders, and payers).
- Create an environment that supports shared learning and celebrates the success of leading-edge organizations investing in pharmacogenomics services.
Visit the Pharmacogenomics Accelerator web page within ASHP’s Innovation Center to learn more about this 12-month program. We also invite you to attend the ASHP Midyear Clinical Meeting & Exhibition’s educational session, “ASHP and University of Minnesota Pharmacogenomics Accelerator: Update from Inaugural Cohort,” to learn more.
